Search Results - Breast cancer type 2 s

Bevacizumab Biosimilar, N297A Mutant C001P.NA Syd Labs

Bevacizumab Biosimilar, N297A Mutant | C001P.NA

Bevacizumab Biosimilar, N297A Mutant. Bevacizumab biosimilar CHO stable cell line is available for licensing to manufacture the bevacizumab biosimilar protein.The research grade bevacizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype...